Rehabilitation and palliation of patients with pancreatic cancer

Part of the Collection de L’Académie Européenne de Médecine de Réadaptation book series (LACADEMIE)


The chief aim of all medical, potentially curative follow-up care measures (recurrence prophylaxis, early detection and therapy of disease recurrence) is to lengthen survival time (fig. 1.3). The actual tumour illness thus represents the focus of curative follow-up care.


Pancreatic Cancer Parenteral Nutrition Enteral Nutrition Pancreatic Cancer Patient Whipple Procedure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. — Alguacil J, Pollan M, Gustavsson P (2003) Occupations with increased risk of pancreatic cancer in the Swedish population. Occup Environ Med 60,8: 570–6PubMedCrossRefGoogle Scholar
  2. — Aspinal F, Hughes R, Higginson I et al. (2002) A user’s guide to the palliative care outcome scale. Palliative care & policy publications. Kings College, LondonGoogle Scholar
  3. — Barat M, Franchignoni F (2004) Assessment in physical medicine and rehabilitation. Maugeri Foundation Books, PI-ME Press PaviaGoogle Scholar
  4. — Bergasa NV (2006) Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am 35,1: 113PubMedCrossRefGoogle Scholar
  5. — Bausewein C, Fegg M, Radbruch L et al. (2005) Validation and clinical application of the German version of the palliative care outcome. J Pain Symptom Manage 30: 51–62PubMedCrossRefGoogle Scholar
  6. — Bundesarbeitsgemeinschaft für Rehabilitation (BAR) (2003) Rahmenempfehlungen zur ambulanten onkologischen Rehabilitation. Schriftenreihe der Bundesarbeitsgemeinschaft für Rehabilitation. FrankfurtGoogle Scholar
  7. — Cella D (1997) The (Fact-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(suppl 2): 13–9PubMedGoogle Scholar
  8. — Delbrück H (2002) Bauchspeicheldrüsenkrebs. Rat und Hilfe für Betroffene und Angehörige. Kohlhammer, StuttgartGoogle Scholar
  9. — Delbrück H, Haupt E (edit.) (1998) Rehabilitationsmedizin. Ambulant — Teilstationär — Stationär. Urban & Schwarzenberg, MünchenGoogle Scholar
  10. — Delbrück H (2004) Krebsschmerz. Rat und Hilfe für Betroffene und Angehörige. Verlag W Kohlhammer, StuttgartGoogle Scholar
  11. — Dunn GP (2002) Surgical palliation in advanced disease: Recent developments. Current science 4: 233–41Google Scholar
  12. — EAPC Expert Working Group (2001) Morphine and alternative opioids in cancer pain. The EAPC recommendation BJC 84: 587Google Scholar
  13. — Epelbaum R, Rosenblatt E, Nasrallah S et al. (2002) Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81: 138–43PubMedCrossRefGoogle Scholar
  14. — Glimelius B et al. (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann oncol 7: 593PubMedGoogle Scholar
  15. — Gordon JN, Trebble T, Ellis RD et al. (2005) Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial. GUT, 54: 540–5PubMedCrossRefGoogle Scholar
  16. — Hocht S, Wiegel T, Siegmann A et al. (2004) Radiochemotherapy in unresectable pancreatic cancer. Front Radiat Ther Oncol 38: 87–93PubMedCrossRefGoogle Scholar
  17. — Holt A, Patel M, Ahmed MM (2004) Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: The treatment of choice.Google Scholar
  18. — Jatoi A, Windschitl HE, Loprinzi CL et al. (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia. J Clin Oncol 20: 567–73PubMedCrossRefGoogle Scholar
  19. — Koski S, Venner P (2000) Chemotherapy-induced nausea and vomiting. In: Nabholtz JM Tonkin K, Aaapro MS et al. (edit) Breast cancer Management. Application of evidence to patient care. M Dunitz London 317–29Google Scholar
  20. — Levy MH, Cohen SD (2005) Sedation for the relief of refractory symptoms in the imminently dying: A fine intentional line. Semin Oncol 32: 237–46PubMedCrossRefGoogle Scholar
  21. — Maguire P, Pitceathly C (2002) Key communication skills and how to acquire them. BMJ 325: 697–700PubMedCrossRefGoogle Scholar
  22. — McLeod RS (1999) Quality of life, nutritional status and gastrointestinal hormone profile following Whipple procedure. Ann Oncol 4(suppl): 281–5CrossRefGoogle Scholar
  23. — Monti D, Yang J (2005) Complementary medicine in chronic cancer care. Semin Oncol 32: 225–31PubMedCrossRefGoogle Scholar
  24. — Moore M, Goldstein D, Hamm J et al. (2007) Erlotinib plus Gemcitabine compared with Gemcitabine alone in patients with advanced pancreatic cancer. J clin Oncol 25,15: 1960–6PubMedCrossRefGoogle Scholar
  25. — Neoptolemos J, Cunningham D et al. (2003) Adjuvant therapy in pancreatic cancer: Historical and current perspectives. Annals of Oncology 14: 675–92PubMedCrossRefGoogle Scholar
  26. — Oyan N (2004) Chemoradiotherapy for pancreatic cancer: Current status and perspectives. Int J Clin Oncol 9,6: 451–7CrossRefGoogle Scholar
  27. — Ogata Y, Hishinuma S (2002) The impact of pylorus-preserving pancreatoduodenectomy on surgical treatment for cancer of the pancreatic head. J Hepatobiliary Pancreat Surg 9,2: 223–32PubMedCrossRefGoogle Scholar
  28. — Patel L, Lindley C (2003) Aprepitant — a novel NK-1receptor antagonist. Expert Opin Pharmacother 4: 2279–96PubMedCrossRefGoogle Scholar
  29. — Rosemeyer D (1996) After-care rehabilitation after pancreas operations. Z Gastroenterol 34,2: 37–40PubMedGoogle Scholar
  30. — Sanders M, Papachristou G, McGrath K et al. (2007) Endoscopic palliation of pancreatic cancer. Gastroenterol Clin North Am 36,2: 455–76PubMedCrossRefGoogle Scholar
  31. — Sehlen S, Fahrmüller H, Herschbach P et al. (2003) Psychometrische Eigenschaft des Stress Index Radio Onkologie (SIRO). Strahlenther Onkol 179,4: 261–9PubMedCrossRefGoogle Scholar
  32. — Sharfman WH, Walsh TD (1990) Has the analgesic efficacy of neurolytic celiac plexus block been demonstrated in pancreatic cancer pain. Pain 41: 267–71PubMedCrossRefGoogle Scholar
  33. — Sindelar WF, Kinsella TJ (1999) Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 10(suppl. 4): 226–30PubMedCrossRefGoogle Scholar
  34. — Shah J, Muthusamg VR (2005) Endoscopic palliation of pancreaticobiliary malignancies. Gastrointest Endosc Clin N Am 15,3: 513–31PubMedCrossRefGoogle Scholar
  35. — Shore S, Vimalachandran D, Raraty MG et al. (2004) Cancer in the elderly: Pancreatic cancer. Surg Oncol 4: 201–10CrossRefGoogle Scholar
  36. — Silverman D, Stewart PA, Blair A et al. (2001) Occupational exposure to pesticides and pancreatic cancer. Am J Ind Med 39,1: 92–9PubMedCrossRefGoogle Scholar
  37. — Smeenk HG, Tran TC, Erdmann J et al. (2004) Survival after surgical management of pancreatic adenocarcinomas: Does curative and radical surgery truly exist? Langenbecks Arch Surg 14Google Scholar
  38. — Tisdale M (2003) Pathogenesis of cancer cachexia. J Support Oncol 1: 159–68PubMedGoogle Scholar
  39. — World Health Organization (1990) Cancer pain relief and palliative care. Technical report, series 804. GenevaGoogle Scholar
  40. — World Health Organization (2001) International classification of functioning, disabilities and health. www. Scholar

Copyright information

© Springer-Verlag France, Paris 2007

Personalised recommendations